Innovent Biologics Enters Hang Seng Index and Two Other Major Indices; Global Capital Markets Recognize Leading Innovator's Value

SAN FRANCISCO and SUZHOU, China , Nov. 23, 2025 /PRNewswire/ -- Innovent Biologics (Stock Code: 01801.HK), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that it has been successfully added as a constituent stock of the Hang Seng Index (HSI) following the release of the Q3 2025 Hang Seng Index Series Quarterly Review results, joining the ranks of blue-chip companies representing Hong Kong's core assets. This milestone makes Innovent the first company that has grown from a biotech into a leading biopharma and been included in the HSI. The company has been concurrently admitted to the Hang Seng China Enterpr